Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.